

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 1681)

CHANGE OF AUTHORISED REPRESENTATIVE

Reference is made to the announcement of Consun Pharmaceutical Group Limited (the “**Company**”) dated 9 July 2021 regarding the changes in composition of the board of directors (the “**Board**”) of the Company and a Board committee (the “**Announcement**”). Unless otherwise specified, capitalised terms used in this announcement have the same meanings as those defined in the Announcement.

The Board hereby announces that as a result of his resignation as an executive Director, Mr. AN Yubao (“**Mr. An**”) has ceased to act as an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Authorised Representative**”) with effect from 9 July 2021. Mr. AN Meng, an executive Director and the chairman of the Board, has been appointed as an Authorised Representative in place of Mr. An with effect from 9 July 2021.

By order of the Board of
Consun Pharmaceutical Group Limited
AN Meng
Chairman

Hong Kong, 23 July 2021

As at the date of this announcement, the Board comprises Mr. AN Meng, Ms. LI Qian, Professor ZHU Quan and Mr. XU Hanxing as executive Directors; Ms. ZHANG Lihua as non-executive Director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.